These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A comparison of propranolol and nadolol pharmacokinetics and clinical effects in thyrotoxicosis. Wilkinson R; Burr WA Am Heart J; 1984 Oct; 108(4 Pt 2):1160-7. PubMed ID: 6148879 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. Jacobs G; Whittem T; Sams R; Calvert C; Ferguson D Am J Vet Res; 1997 Apr; 58(4):398-403. PubMed ID: 9099387 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of propranolol and sotalol in hyperthyroidism. Aro A; Anttila M; Korhonen T; Sundquist H Eur J Clin Pharmacol; 1982; 21(5):373-7. PubMed ID: 7075642 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics in drug therapy. I: Propranolol hydrochloride as adjunct therapy in the treatment of thyrotoxicosis. Robayo JR Am J Hosp Pharm; 1976 Feb; 33(2):169-73. PubMed ID: 56890 [TBL] [Abstract][Full Text] [Related]
8. Propranolol as primary therapy for thyrotoxicosis. Mazzaferri EL; Reynolds JC; Young RL; Thomas CN; Parisi AF Arch Intern Med; 1976 Jan; 136(1):50-6. PubMed ID: 1108824 [TBL] [Abstract][Full Text] [Related]
9. The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration. Feely J; Crooks J; Stevenson IH Br J Clin Pharmacol; 1981 Jul; 12(1):73-8. PubMed ID: 6264937 [TBL] [Abstract][Full Text] [Related]
10. Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol. Hallengren B; Nilsson OR; Karlberg BE; Melander A; Tegler L; Wåhlin-Boll E Eur J Clin Pharmacol; 1982; 21(5):379-84. PubMed ID: 7075643 [TBL] [Abstract][Full Text] [Related]
13. Effects of thyroid dysfunction on propranolol kinetics. Riddell JG; Neill JD; Kelly JG; McDevitt DG Clin Pharmacol Ther; 1980 Nov; 28(5):565-74. PubMed ID: 7438675 [TBL] [Abstract][Full Text] [Related]
14. Propranolol and the hypercalcaemia of thyrotoxicosis. Feely J Acta Endocrinol (Copenh); 1981 Dec; 98(4):528-32. PubMed ID: 7304079 [TBL] [Abstract][Full Text] [Related]
15. No enhanced elimination of propranolol in patients with hyperthyroidism. Ishizaki T; Masuno M; Tawara K Res Commun Chem Pathol Pharmacol; 1980 Sep; 29(3):473-85. PubMed ID: 7423023 [TBL] [Abstract][Full Text] [Related]
16. Steady state pharmacokinetics of propranolol in Saudi Arabian patients and comparison with data for different populations. el-Yazigi A; el-Baage T; al-Humaidan A; Yusuf A J Clin Pharmacol; 1990 Feb; 30(2):144-50. PubMed ID: 2312765 [TBL] [Abstract][Full Text] [Related]
17. Kinetics and cardiac effects of propranolol in humans. Ochs HR; Grube E; Greenblatt DJ; Knüchel M; Bodem G Klin Wochenschr; 1982 May; 60(10):521-5. PubMed ID: 7098380 [TBL] [Abstract][Full Text] [Related]
18. No stereoselective first-pass hepatic extraction of propranolol. Jackman GP; McLean AJ; Jennings GL; Bobik A Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593 [TBL] [Abstract][Full Text] [Related]
19. Plasma protein binding of propranolol and isoprenaline in hyperthyroidism and hypothyroidism. Kelly JG; McDevitt DG Br J Clin Pharmacol; 1978 Aug; 6(2):123-7. PubMed ID: 678388 [TBL] [Abstract][Full Text] [Related]
20. Oral propranolol in hypercalcemia associated with apathetic thyrotoxicosis. Shahshahani MN; Palmieri GM Am J Med Sci; 1978; 275(2):199-202. PubMed ID: 665723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]